Elane Is Highly Expressed In Leukemia Patients And Predicts Poor Survival

ELANE (Elastase, Neutrophil Expressed), which has been identified as an oncogene in various tumors, is associated with neutropenia, both cyclic and autosomal dominant forms. However, little is known about ELANE on leukemia progression. To better understand the role of ELANE in leukemia progression, the expression level of ELANE, as well as correlation and survival analyses, was performed in patients with leukemia. Gene expression of ELANE on the normal monocytes and myeloid leukemia samples was obtained and compared via Oncomine. Correlation of ELANE and proto-oncogenes includes MYC and TP53 was assessed. The clinical prognostic value of ELANE was found to be elevated using Metzeler Acute myeloid leukemia microarray. As a result, ELANE was found to be highly expressed in the leukemia samples compared to normal monocytes. ELANE was found to be positively correlated with MYC expression, whereas it was negatively correlated with TP53 expression. Additionally, high expression of ELANE was associated with a relatively shorter survival time in leukemia patients, suggesting that ELANE is an oncogene in leukemia development. In conclusion, ELANE acts as a pro-oncogene in leukemia, which provides a potential therapeutic target.